Loading...
XSHE
002082
Market cap1.11bUSD
Jul 10, Last price  
12.29CNY
1D
0.24%
1Q
-58.76%
IPO
35.35%
Name

Wepon Pharmaceutical Holding Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002082 chart
P/E
—
P/S
6.73
EPS
—
Div Yield, %
0.65%
Shrs. gr., 5y
0.14%
Rev. gr., 5y
-10.36%
Revenues
1.12b
-22.59%
5,835,868,4796,347,707,4308,053,707,36010,873,866,11210,972,922,37911,786,336,48811,451,694,09311,572,197,7719,183,466,30714,635,458,223736,219,71716,691,270,12213,701,855,5831,930,601,8661,930,601,8661,786,428,3081,786,428,3081,541,938,5841,443,365,2221,117,324,092
Net income
-167m
L
74,047,353121,048,269151,985,726158,644,10586,409,315111,557,568107,530,81263,024,60069,735,59098,213,450162,202,603294,522,923284,935,739166,509,677166,509,68974,322,52793,260,30149,208,89155,440,976-167,236,985
CFO
604m
+402.39%
3,500,56612,453,463253,062,50668,134,391162,264,5910202,732,245234,352,539140,310,21416,762,923310,712,8490135,396,1000151,006,12022,085,1880-72,869,795120,221,961603,980,072
Dividend
Jul 11, 20240.08 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1985 and headquartered in Taizhou, China, Wanbangde Pharmaceutical Holding Group Co., Ltd. primarily focuses on the research, development, manufacturing, and distribution of traditional Chinese medicines, active pharmaceutical ingredients (APIs), and various medicinal preparations. The company also extends its operations into the medical technology field, developing products such as orthopedic implant devices, general medical equipment, protective gear, and disposable sterile polymer medical consumables. Complementary to its product offerings, it provides specialized hospital engineering services. Initially known as Wanbangde New Building Materials Co., Ltd., the company officially adopted its current name, Wanbangde Pharmaceutical Holding Group Co., Ltd., in April 2020.
URL
https://www.dongliang.com.cn/
IPO date
Nov 20, 2006
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT